Plasma metabolites associated with colorectal cancer: A discovery-replication strategy

Anne J.M.R. Geijsen, Stefanie Brezina, Pekka Keski-Rahkonen, Andreas Baierl, Thomas Bachleitner-Hofmann, Michael M. Bergmann, Juergen Boehm, Hermann Brenner, Jenny Chang-Claude, Fränzel J.B. van Duijnhoven, Biljana Gigic, Tanja Gumpenberger, Philipp Hofer, Michael Hoffmeister, Andreana N. Holowatyj, Judith Karner-Hanusch, Dieuwertje E. Kok, Gernot Leeb, Arve Ulvik, Nivonirina RobinotJennifer Ose, Anton Stift, Petra Schrotz-King, Alexis B. Ulrich, Per Magne Ueland, Ellen Kampman, Augustin Scalbert, Nina Habermann, Andrea Gsur, Cornelia M. Ulrich

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Colorectal cancer is known to arise from multiple tumorigenic pathways; however, the underlying mechanisms remain not completely understood. Metabolomics is becoming an increasingly popular tool in assessing biological processes. Previous metabolomics research focusing on colorectal cancer is limited by sample size and did not replicate findings in independent study populations to verify robustness of reported findings. Here, we performed a ultrahigh performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS) screening on EDTA plasma from 268 colorectal cancer patients and 353 controls using independent discovery and replication sets from two European cohorts (ColoCare Study: n = 180 patients/n = 153 controls; the Colorectal Cancer Study of Austria (CORSA) n = 88 patients/n = 200 controls), aiming to identify circulating plasma metabolites associated with colorectal cancer and to improve knowledge regarding colorectal cancer etiology. Multiple logistic regression models were used to test the association between disease state and metabolic features. Statistically significant associated features in the discovery set were taken forward and tested in the replication set to assure robustness of our findings. All models were adjusted for sex, age, BMI and smoking status and corrected for multiple testing using False Discovery Rate. Demographic and clinical data were abstracted from questionnaires and medical records.
Original languageEnglish
Pages (from-to)1221-1231
JournalInternational Journal of Cancer
Volume145
Issue number5
DOIs
Publication statusPublished - 1 Sept 2019
Externally publishedYes

Funding

Key words: colorectal cancer, metabolomics, discovery-replication approach, UHPLC-QTOF-MS Abbreviations: BCAA: branched chain amino acid; BMI: body mass index; CI: confidence interval; CORSA: Colorectal Cancer Study of Austria; ESI: electrospray ionization; FDR: false discovery rate; FIT: fecal Immunochemical Testing; IARC: International Agency for Research on Cancer; IQR: interquartile range; LysoPEs: lysophosphatidylethanolamines; LysoPCs: lysophosphatidylcholines; MNA: 1-methylnicotinamide; MS: mass spectrometry; MSI: the Metabolomics Standards Initiative; OR.std: log standardized odds ratios; (Q)TOF: (Quadrupole) time-of-flight; SD: standard deviation; TCA: tricarboxylic acid; UHPLC: ultrahigh performance liquid chromatography; WHO: World Health Organization Additional Supporting Information may be found in the online version of this article. †A.J.M.R.G. and S.B. are the shared co-first authors. N.H., A.G., and C.M.U. contributed equally to this work. Grant sponsor: Austrian Science Fund; Grant number: I1578-B19; Grant sponsor: Bundesministerium für Bildung und Forschung; Grant number: 01KT1512; Grant sponsor: Huntsman Cancer Foundation; Grant sponsor: KWF Kankerbestrijding; Grant number: UW2013-6397; Grant sponsor: National Cancer Institute; Grant numbers: R01 CA189184, R01 CA207371, U01 CA206110; Grant sponsor: National Cancer Institute, INCa, France; Grant number: 2014-007; Grant sponsor: National Human Genome Research Institute; Grant number: Ruth L. Kirschstein National Research Service Awar; Grant sponsor: Netherlands Organization for Health Research and Development; Grant sponsor: The Research Council of Norway; Grant number: 236564/H10 DOI: 10.1002/ijc.32146 This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. History: Received 27 Nov 2018; Accepted 8 Jan 2019; Online 21 Jan 2019 Correspondence to: Andrea Gsur, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna Borschkegasse 8a, Vienna, 1090, Austria, Tel.: 0043-1-40-160-57541, E-mail: [email protected] The authors would like to acknowledge the contribution of all ColoCare and CORSA Study participants. ColoCare ColoCare samples were stored by the liquid biobank of the National Center for Tumor Diseases according to the SOPs of the Biomaterialbank Heidelberg. Lin Zielske, Anett Brendel, Renate Skatula, Marita Wenzel supported biobanking at the National Center for Tumor Diseases. In addition, we would like to thank Rifraz Farook and Werner Diehl for their data management support and the ColoCare team, specifically Torsten Kölsch, Clare Abbenhardt-Martin, Susanne Jakob, and Judith Kammer for patient recruitment and follow-up. CORSA We kindly thank Michael Micksche (Institute of Cancer Research, Department of Medicine I, Medical University of Vienna), Karl Mach, Azita Deutinger-Permoon (KRAGES, Austria), and their co-workers for supporting CORSA recruitment. In addition, we would like to acknowledge Elisabeth Feik, Cornelia Zöchmeister, Ricarda Staudinger, Anna Doralt, and Marie Luise Brunner for patient recruitment, sample processing, and follow-up.

FundersFunder number
Biomaterialbank Heidelberg
National Center for Tumor Diseases
National Research Service Awar
National Human Genome Research Institute
National Cancer InstituteR01 CA189184, R01 CA207371, U01CA206110, 2014-007
Huntsman Cancer Foundation
ZonMw
Austrian Science FundI1578-B19
KWF KankerbestrijdingUW2013-6397
Norges forskningsråd236564/H10 DOI
Medizinische Universität Wien
Bundesministerium für Bildung und Frauen01KT1512

    Fingerprint

    Dive into the research topics of 'Plasma metabolites associated with colorectal cancer: A discovery-replication strategy'. Together they form a unique fingerprint.

    Cite this